79 results
SC TO-T/A
PNT
POINT Biopharma Global Inc.
8 Nov 23
Third party tender offer statement (amended)
5:06pm
the subheading “Certain Litigation” in Section 16 — “Certain Legal Matters; Regulatory Approvals” of the Offer to Purchase and replacing
SC TO-T/A
PNT
POINT Biopharma Global Inc.
27 Oct 23
Third party tender offer statement (amended)
4:15pm
” of the Offer to Purchase:
“Certain Litigation
In connection with the Offer and Merger Agreement, three complaints have been filed as individual
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
, as well as its ability to attract and retain key personnel while the transaction is pending.
Litigation Risk. The execution of the Merger Agreement … , the completion of the Offer and the consummation of the Merger increases the risk of litigation against POINT.
Interim Operating Covenants. The Merger
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
include giving it to the Department of Justice for civil and criminal litigation and to cities, states, the District of Columbia, and U.S
SC TO-T
EX-99
552bxnqxzpp kzzs9lo
13 Oct 23
Third party tender offer statement
6:52am
SC14D9C
EX-99.2
9ct1p0tq k2m0b4
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.3
ckzymsh e7d
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-2.1
vvy v55w57
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.1
blato
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.1
legdt a2f
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.2
b6ubwacbxs q36p9c6
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-2.1
440 avttlhva2zqy
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.3
n6obnop32
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
0byt57
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
ia0fsu6xfggn1j
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
e7tjyu83ismjlr7hvrgv
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm